Neuro NTK

1. Summary

Ranks

Liquidity

-

Developer

-

Social

47

Momentum (beta)

0

Stack Rank™

-

Price

$0.000252660000 0.0%

Market Cap

$145,550.00 (#6676)

Supply

/

Tags

Ethereum Ecosystem

More Metrics

Price
52W High price	$0.01
52W High date	7th Sep 2022 (2 years ago)
All Time High (ATH) Date	13th May 2025 (2 weeks ago)
All Time Low (ATL) Date	13th May 2025 (2 weeks ago)

Supply & Trading Volume

Less Metrics

Description

Overview

Read More

Overview

Neuro NTK (NeuroToolKit) is a collaborative project between academia and industry aimed at advancing research and informating developments in diagnostic and treatment solutions for Alzheimer’s disease, neurodegeneration, and other neurological disorders. The initiative focuses on generating high-quality, reproducible, and comparable clinical biomarker data to accelerate the validation of biomarkers for clinical utility.

Core Components

• Biomarker Assays: The NTK offers a comprehensive portfolio of prototype assays that measure biomarkers across CSF and serum/plasma platforms. The assays are designed for use on the fully automated Elecsys platform in qualified NTK labs, ensuring high-quality, reproducible data.

• NTKApp: A cloud-based analytics platform that improves the interpretation of neurologically relevant immunoassay data. It provides users with a unified environment to upload, curate, analyze, and compare biomarker datasets and results. Additionally, users can import and run their own statistical analysis pipelines, which can be shared with the NTK community.

• Data Analysis and Collaboration: The NTK enables collaborative research by providing a robust digital research environment, facilitating the sharing and interpretation of data across various cohorts. This collaboration accelerates the discovery and development of biomarkers suitable for clinical trials and routine medical practice.

• ADDI NeuroToolKit Data Hackathon: A virtual event that brings together researchers, clinicians, data scientists, and biostatisticians to explore the clinical utility of biomarkers in Alzheimer’s disease. Participants use the NTKApp, EPAD datasets, and statistical analysis tools available on the AD Workbench to explore standardized and customized analyses.

Goals and Future Directions

• Clinical Utility and Validation: Clarify the clinical utility of biomarkers in Alzheimer’s disease and other neurological disorders

• IVD Development: Inform the development of In Vitro Diagnostics (IVD) biomarkers that support clinical screening, diagnosis, prognosis, and drug monitoring

• Partnerships and Expansion: Encourage collaboration among partners, including academia and industry, to accelerate biomarker research and development.

Show Less